<DOC>
	<DOCNO>NCT00003135</DOCNO>
	<brief_summary>RATIONALE : Hyperthermia therapy kill tumor cell heat several degree body temperature . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining chemotherapy hyperthermia may kill tumor cell . PURPOSE : This phase II trial study well give fluorouracil liposomal doxorubicin together systemic hyperthermia work treat patient metastatic breast , ovarian , endometrial , cervical cancer .</brief_summary>
	<brief_title>Whole Body Hyperthermia Combined With Chemotherapy Treating Patients With Metastatic Breast , Ovarian , Endometrial , Cervical Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Evaluate tumor response toxicity induce fluorouracil doxorubicin HCl liposome combine mild systemic hyperthermia patient metastatic breast , ovarian , endometrial , cervical cancer . OUTLINE : This time-escalation study systemic hyperthermia . Patients receive fluorouracil IV continuously 24 hour day 1-5 doxorubicin HCl liposome IV 30 minute day 6 . Beginning day 7 , patient receive heat apply 6-24 hour ( 6-hour sequential treatment ) use mild hyperthermia-induction device . Treatment repeat every 4-5 week total 4 course . Patients achieve less complete response disease progression may receive additional course chemotherapy alone . Cohorts 5 patient receive escalate duration hyperthermia recommend phase II duration determine . The recommended phase II duration hyperthermia define level precede 1 5 patient experience measurable toxicity . ( Phase I close 9/28/01 ) Patients follow 4 week every 6 month 1 year . PROJECTED ACCRUAL : A maximum 34 patient accrue study within 48 month .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Fever</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm metastatic breast , ovarian , endometrial , cervical carcinoma Measurable evaluable disease No brain metastases No hepatic involvement great 80 % No lung involvement great 30 % Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : 18 Sex : Not specify Menopausal status : Not specify Performance status : Zubrod 02 Life expectancy : At least 12 week Hematopoietic : Absolute granulocyte count great 1,500/mm^3 Platelet count great 90,000/mm^3 Normal bone marrow cellularity bone marrow biopsy Thrombin time le 17 sec Fibrinogen great 200 mg/dL FSP le 40 No coagulopathy Hepatic : Bilirubin le 2.0 mg/dL SGPT le 2 time normal PT le 14 sec PTT le 35 sec Renal : BUN le 25 mg/dL Creatinine clearance least 45 mL/min Cardiovascular : Normal cardiovascular system Resting ventricular ejection fraction great 40 % No prior myocardial infarction No symptomatic coronary artery disease No unstable blood pressure No thromboembolic disease Neurologic : No seizure CNS disorder Negative computerize tomographic scan brain Pulmonary : FEV_1 great 70 % predict Arterial pressure oxygen great 60 mmHg room air appropriate pressure carbon dioxide pH value No history cardiopulmonary respiratory disease Other : No serious concurrent medical illness No diabetes mellitus PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Prior chemotherapy allow Endocrine therapy : No adrenal corticosteroid Radiotherapy : Not specify Surgery : Not specify Other : No concurrent cardiac glycoside , antianginal therapy , antiarrhythmics No concurrent vasodilator , anticoagulant , thrombolytic agent , aspirin</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2008</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
	<keyword>recurrent cervical cancer</keyword>
	<keyword>stage IVB cervical cancer</keyword>
	<keyword>stage IVA cervical cancer</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>stage IV endometrial carcinoma</keyword>
	<keyword>recurrent endometrial carcinoma</keyword>
	<keyword>stage IV ovarian germ cell tumor</keyword>
	<keyword>recurrent ovarian germ cell tumor</keyword>
	<keyword>male breast cancer</keyword>
</DOC>